[
  {
    "ts": "2026-02-28T04:28:27+00:00",
    "headline": "Merck Reshapes Drug Business As Keytruda Era Nears Turning Point",
    "summary": "Merck (NYSE:MRK) is restructuring its pharmaceutical business into two divisions, Oncology and Specialty/Pharma & Infectious Diseases, with new executive leadership. The move is described as a response to the upcoming patent expiration for Keytruda, the company’s flagship cancer therapy. Alongside the reorganization, Merck released new late stage clinical data on Keytruda combinations in cancer and on HIV and RSV treatment candidates. For you as an investor, this is a meaningful shift for a...",
    "url": "https://finance.yahoo.com/news/merck-reshapes-drug-business-keytruda-042827053.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "422ad4e4-63e9-305a-ab05-ab7cda7dea60",
      "content": {
        "id": "422ad4e4-63e9-305a-ab05-ab7cda7dea60",
        "contentType": "STORY",
        "title": "Merck Reshapes Drug Business As Keytruda Era Nears Turning Point",
        "description": "",
        "summary": "Merck (NYSE:MRK) is restructuring its pharmaceutical business into two divisions, Oncology and Specialty/Pharma & Infectious Diseases, with new executive leadership. The move is described as a response to the upcoming patent expiration for Keytruda, the company’s flagship cancer therapy. Alongside the reorganization, Merck released new late stage clinical data on Keytruda combinations in cancer and on HIV and RSV treatment candidates. For you as an investor, this is a meaningful shift for a...",
        "pubDate": "2026-02-28T04:28:27Z",
        "displayTime": "2026-02-28T04:28:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-reshapes-drug-business-keytruda-042827053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-reshapes-drug-business-keytruda-042827053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]